Athena Athena

X
[{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Longitude Capital","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rivus Pharmaceuticals Launches with $35 Million Series A Financing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rivus Pharmaceuticals Announces Positive Data from Phase 2a Clinical Trial of Lead Candidate HU6, Demonstrating Fat Reduction and Weight Loss in High BMI Participants","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$132.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rivus Pharmaceuticals Closes $132 Million Series B Financing to Advance HU6 for the Treatment of Obesity and Cardio-Metabolic Disorders","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rivus Pharmaceuticals Announces Completion of Enrollment in Phase 2a HuMAIN Trial of HU6","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by Rivus Pharmaceuticals

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            HU6 is an investigational controlled metabolic accelerator (CMA) which is under phase 2 clinical development for the treatment of heart failure with preserved ejection fraction.

            Lead Product(s): HU6

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: HU6

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 05, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The financing will further support clinical advancement of lead candidate HU6, a first-in-class Controlled Metabolic Accelerator (CMA) designed to treat cardio-metabolic disease by addressing obesity, a primary driver of disease.

            Lead Product(s): HU6

            Therapeutic Area: Nutrition and Weight Loss Product Name: HU6

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: RA Capital Management

            Deal Size: $132.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing September 22, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            HU6 leads a pipeline of first-in-class, orally administered Controlled Metabolic Accelerators that accelerate fat metabolism and treat the underlying cause of type 2 diabetes, HFpEF, NASH, and other cardiovascular and metabolic diseases met primary and secondary endpoint.

            Lead Product(s): HU6

            Therapeutic Area: Endocrinology Product Name: HU6

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 09, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Rivus is currently conducting a Phase 2a clinical study with its lead CMA therapeutic, HU6. The Series A financing will enable Rivus to advance a pipeline of CMA therapies to treat a range of metabolic conditions as well as cardiovascular diseases.

            Lead Product(s): HU6

            Therapeutic Area: Endocrinology Product Name: HU6

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Longitude Capital

            Deal Size: $35.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing July 20, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY